
Polyvinylpyrrolidone 30 For Pharmaceutical
CTFA name :1-vinyl-2-pyrrolidone homopolymer
CAS No.:9003-39-8
Molecular formula:(C6H9NO)n
Pharmaceutical-grade PVP K30 / Povidone K30 excipient — manufactured under GMP in Inner Mongolia, China, with multi-pharmacopeia compliance and FDA DMF support USP-NFEP (Povidonum)/CP/JP/BP FDA DMF Filed FDA IID Listed ICH Q3D / Q3CGMP Certified REACH Registered HALAL
Ulanqab Kema New Material Co., Ltd. is one of the most experienced manufacturers and suppliers of polyvinylpyrrolidone 30 for pharmaceutical in China. Please rest assured to wholesale high quality polyvinylpyrrolidone 30 for pharmaceutical made in China here from our factory. If you have any enquiry about free sample, please feel free to email us.
Product Overview

For pharmaceutical R&D scientists, formulation developers, and procurement teams specifying excipients for human-use drug products, polyvinylpyrrolidone 30 for pharmaceutical is the most widely used pharmaceutical-grade PVP binder in the industry, with a K-value of 27.0–32.0 and a viscosity-average molecular weight of approximately 44,000–58,000 Da that gives the optimal balance of binding strength, water solubility, and film-forming behavior required by modern solid-dosage, coating, liquid, and sterile dosage forms.
Manufactured by Ulanqab Kema New Material Co., Ltd. in our vertically integrated facility in Inner Mongolia, China - where we control every step from N-vinyl-2-pyrrolidone (NVP) monomer polymerization to finished powder packaging - our pharmaceutical-grade PVP K30 is tested against USP-NF, EP (Povidonum), CP, JP, and BP monographs, supported by FDA Drug Master File (DMF) filings, EU/UK/Turkey/Korea REACH registrations, and certified to ISO 9001, ISO 14001, ISO 45001, ISO 50001, and GMP management systems.
Polyvinylpyrrolidone (povidone) has been continuously evaluated in pharmaceutical use for more than seventy years, with a well-characterized safety profile, low sensitization potential, and no bioaccumulation due to its defined molecular weight range. It is listed in the FDA Inactive Ingredients Database (IID) for oral, topical, ophthalmic, and parenteral routes, and is approved as an EU food additive (E1201) for beverage clarification. Every batch ships with a Certificate of Analysis (COA), Material Safety Data Sheet (MSDS), Certificate of Origin (COO), and batch-specific microbiological and impurity data, giving formulation scientists a fully documented excipient for global regulatory submissions. Free evaluation samples of 100 g–500 g are available for qualified buyers.
Why Specify Polyvinylpyrrolidone 30 For Pharmaceutical
- Decades of Pharmaceutical Use with Well-Characterized Safety: Polyvinylpyrrolidone (povidone) has been used in human pharmaceutical formulations since the 1940s. PVP K30 is non-ionic, physiologically inert, chemically stable across pH 1–14, and has a very low sensitization potential. It does not bioaccumulate because the renal clearance threshold is below the K30 molecular weight range. These properties make PVP K30 a trusted excipient for oral solid dosage, ophthalmic, transdermal, and parenteral applications.
- Multi-Pharmacopeia Compliance for Global Registration: Monographed in USP-NF, EP (Povidonum), CP, JP, and BP; listed in the FDA Inactive Ingredients Database (IID) for oral, topical, ophthalmic, and parenteral routes; approved as EU food additive E1201; HALAL certified. DMF reference letters are available for FDA, EMA, and other authority submissions.
- Solubilization of Poorly Soluble APIs (BCS Class II): PVP K30 is the most widely used polymer carrier for amorphous solid dispersions of BCS Class II active pharmaceutical ingredients. The 1:2 to 1:10 drug-to-polymer ratio range, combined with K30's hydrogen-bond interaction with many drug molecules, significantly improves apparent solubility and oral bioavailability.
- Manufactured from In-House NVP Monomer: Our continuous NVP monomer line (5,000 MT/year single-line capacity) feeds the K30 polymerization step directly. Vertical integration means fewer raw-material supply risks, consistent impurity profiles, and batch-to-batch K-value reproducibility within ±1 unit.
- Complete Documentation and Technical Support: Every batch ships with COA, MSDS, COO, microbiological report, and optional DMF letter. Our regulatory and technical teams support supplier qualification, audit questionnaires, formulation trials, compatibility studies, and stability study design.

Quality, Safety & Regulatory Pathway
Polyvinylpyrrolidone 30 for pharmaceutical is synthesized by free-radical polymerization of N-vinyl-2-pyrrolidone (NVP) and meets all major pharmacopeial monographs simultaneously. The combination of pharmacopeial compliance, FDA IID listing, DMF support, and impurity control under ICH Q3D and ICH Q3C guidelines is what allows our PVP K30 to be specified in drug products registered for global markets.
|
Regulatory Element |
Status / Details |
|
Pharmacopeial Monographs |
USP-NF, EP (Povidonum), CP, JP, BP |
|
FDA Listing |
Inactive Ingredients Database (ID) - oral, topical, ophthalmic, parenteral |
|
FDA Drug Master File |
DMF filed for pharmaceutical-grade PVP K-series and PVP-I |
|
EU Regulatory |
EU food additive E1201; EU REACH registered |
|
UK Regulatory |
UK REACH registered |
|
Other REACH |
Turkey REACH, South Korea REACH |
|
Religious / Dietary |
HALAL certified, Kosher certified |
|
Impurity Control |
ICH Q3D elemental impurities; ICH Q3C Class 1 solvent limits |
|
Quality System |
GMP clean production; ISO 9001 / 14001 / 45001 / 50001 |
|
Automotive / Industrial |
IATF 16949 |
|
Bioburden / Microbiological |
TAMC ≤ 1000 CFU/g; TYMC ≤ 100 CFU/g; absence of E. coli (USP <61>/<62>) |
|
Elemental Impurities |
Controlled to ICH Q3D limits per route of administration |
|
Residual Solvent |
Class 1 solvents below Q3C limits; manufacturing uses water/ethanol |
|
Allergen / BSE/TSE |
No materials of animal or human origin; no BSE/TSE risk |
|
Latex / DEHP |
Not used in manufacturing or packaging |
Drug Formulation Safety Profile
PVP K30 is selected for pharmaceutical dosage forms because of its well-established safety and toxicology profile:
- Non-ionic and chemically inert - PVP does not react with cationic, anionic, or neutral APIs, and does not catalyze drug degradation. This is critical for moisture-sensitive or oxidation-prone APIs.
- No body accumulation - PVP K30's molecular weight (44,000–58,000 Da) is well below the renal threshold (approximately 70,000 Da), so any absorbed fraction is rapidly excreted unchanged by the kidneys. This distinguishes PVP from higher-molecular-weight polymers that require chronic-toxicity evaluation.
- Wide pH stability - PVP K30 is stable from pH 1 to pH 14, allowing formulation in acidic, neutral, and alkaline environments without polymer degradation.
- Thermal stability - Glass transition temperature (Tg) of approximately 150–180°C allows hot-melt extrusion processing, spray drying above 100°C inlet, and standard fluid-bed drying.
- Sterilization compatibility - PVP K30 can be sterile-filtered (0.22 μm) for parenteral and ophthalmic preparations, and is compatible with autoclave conditions at 121°C / 15 min for terminal sterilization of liquid formulations.
No preservatives required in some applications - PVP K30's stabilizing effect on suspensions and emulsions can reduce or eliminate the need for additional preservatives in certain formulations.
Products Description
|
Test Item |
Specification |
Typical Value |
Test Method / Reference |
|
Product Name |
Polyvinylpyrrolidone K30 (PVP K-30, Povidone K30) |
- |
- |
|
CTFA Name |
1-vinyl-2-pyrrolidone homopolymer |
- |
- |
|
CAS Number |
9003-39-8 |
- |
- |
|
HS Code |
39059900 |
- |
- |
|
INN / Pharmacopeial Name |
Povidone / Povidonum (EP) |
- |
- |
|
Molecular Formula |
(C₆H₉NO)n |
- |
- |
|
Molecular Weight (viscosity-avg) |
~44,000 – 58,000 Da |
- |
Mark-Houwink |
|
Appearance |
White or yellowish-white free-flowing powder |
Complies |
Visual / USP |
|
Odor |
Odorless or nearly odorless |
Complies |
Organoleptic |
|
K-Value |
27.0 – 32.0 |
30.30 |
USP / EP (Fikentscher, 1% aq. sol., 25°C) |
|
Identification (A, B, C, D, E) |
Conforms |
Complies |
USP / EP / CP |
|
pH (5% aqueous solution) |
3.0 – 5.0 (USP allows 3.0 – 7.0) |
3.81 |
USP / EP |
|
Moisture / Loss on Drying |
≤ 5.0% |
3.32% |
USP <731> / EP 2.2.32 |
|
Residue on Ignition |
≤ 0.1% |
0.02% |
USP / EP |
|
Sulphated Ash |
≤ 0.1% |
- |
EP 2.4.14 |
|
Nitrogen Content |
11.5% – 12.8% |
12.0% |
Kjeldahl |
|
1-Vinylpyrrolidin-2-one (residual monomer) |
≤ 0.001% (≤ 10 ppm) |
0.40 ppm |
HPLC / USP |
|
Aldehydes (as acetaldehyde) |
≤ 0.05% (≤ 500 ppm) |
125 ppm |
USP / EP |
|
Peroxides (as H₂O₂) |
≤ 400 ppm |
207 ppm |
USP / EP |
|
Hydrazine |
≤ 1.0 ppm |
< 1.0 ppm |
USP / EP |
|
Heavy Metals (as Pb) |
≤ 10 ppm |
< 10 ppm |
USP <231> / ICH Q3D |
|
Formic Acid |
≤ 0.5% |
< 0.5% |
HPLC / USP |
|
2-Pyrrolidone |
≤ 3% |
< 3% |
HPLC / USP |
|
Glass Transition Temperature (Tg) |
150 – 180°C |
- |
DSC |
|
Bulk Density |
0.30 – 0.50 g/cm³ |
- |
USP <616> |
|
Hygroscopicity |
Hygroscopic - store in airtight containers |
- |
- |
|
Solubility |
Freely soluble in water, ethanol, isopropanol; soluble in many organic solvents |
- |
- |
|
Microbial Limits |
TAMC ≤ 1000 CFU/g; TYMC ≤ 100 CFU/g; E. coli absent |
Complies |
USP <61>/<62> / EP 2.6.12 |
|
Elemental Impurities (ICH Q3D) |
Within PDE limits per route |
Complies |
ICP-MS / ICH Q3D |
|
Residual Solvents (ICH Q3C) |
Class 1 below Q3C limits; water/ethanol only |
Complies |
GC / ICH Q3C |
|
Allergen / BSE-TSE Status |
No animal/human origin materials |
Complies |
Manufacturer declaration |
|
Shelf Life |
24 months (unopened, proper storage) |
- |
Stability study |
|
Storage Conditions |
Tightly closed containers, cool dry place, 15 – 25°C recommended, protect from moisture |
- |
- |
Pharmaceutical Applications
|
Dosage Form |
Application |
Function / Benefit |
|
Oral Solid - Wet Granulation |
Tablet and granule binder at 2–5% w/w as 5–10% aqueous or ethanolic solution |
Strong inter-particle bridges, improved compressibility and hardness |
|
Oral Solid - Direct Compression |
Dry binder at 2–5% w/w |
Compatible with moisture-sensitive APIs; improved powder flow |
|
Oral Solid - Roller Compaction |
Dry granulation binder |
Maintains tablet hardness without over-densification |
|
Oral Solid - Solid Dispersion |
Carrier matrix for BCS Class II APIs (drug:polymer = 1:2 to 1:10) |
Enhances apparent solubility and oral bioavailability of poorly soluble drugs |
|
Oral Solid - Film Coating |
Auxiliary film former / pore former at 1–5% w/w |
Improves film flexibility, pigment dispersion, and adhesion to tablet core |
|
Oral Liquid / Suspension |
Suspending agent and viscosity modifier at 0.1–5% w/v |
Prevents sedimentation; stabilizes taste-masked suspensions |
|
Ophthalmic |
Viscosity enhancer at 0.5–5% w/v in eye drops |
Prolongs corneal contact time, improves patient comfort |
|
Transdermal |
Pressure-sensitive adhesive (PSA) matrix component at 5–20% w/w |
Enhances drug flux through skin (e.g., rotigotine patches); forms drug-polymer complexes |
|
Sublingual / Buccal |
Binder and film former in fast-dissolving films and tablets |
Quick dissolution, pleasant mouthfeel |
|
Topical - Creams, Gels, Lotions |
Film former, thickener, stabilizer at 0.5–3% w/w |
Clear, non-tacky finish; compatible with active ingredients |
|
Veterinary / Animal Health |
Same applications as human pharma |
Multi-pharmacopeial compliance supports global veterinary dossiers |
Manufacturing & Supplier Capability
Ulanqab Kema New Material Co., Ltd. is located in Mengwei New Material Industrial Park, Qahar Right Rear Banner, Ulanqab City, Inner Mongolia, China. Founded in June 2017, the company is registered with RMB 59.58 million capital and RMB 110 million fixed assets, employs 150 people, and records annual sales exceeding RMB 200 million. Production capacity includes 5,000 tons of NVP monomer per year, 1,500 tons of PVP-K series (K17, K25, K30, K60, K90), and 1,000 tons of PVPP / VA64 / PVP-I. These figures reflect our current, expanded operations; the original page described initial-phase numbers that have since been scaled up.
|
Capability Element |
Details |
|
Vertical Integration |
In-house NVP monomer production (5,000 MT/year) → continuous polymerization → finished powder |
|
Quality Management |
GMP clean production workshops; ISO 9001 / ISO 14001 / ISO 45001 / ISO 50001 certified |
|
Analytical Capability |
HPLC, GC, ICP-MS, UV-Vis, Karl Fischer, Brookfield viscometer, full pharmacopeial wet chemistry in-house |
|
Documentation per Batch |
COA (batch-specific), MSDS, COO, microbiological report, packing list, invoice, B/L |
|
Regulatory Files |
FDA DMF for PVP K-series; EU / UK / Turkey / Korea REACH registrations; HALAL & Kosher; IATF 16949 |
|
R&D Investment |
Over RMB 30 million invested in R&D in the past five years; 6 invention patents and 33 utility model patents |
|
Reliability Record |
99.98% pharmaceutical-grade PVP batch pass rate; 99.39% on-time delivery rate; 89% three-year customer repeat purchase rate |
|
Customer Base |
300+ domestic and 100+ international customers across the USA, UK, Portugal, Italy, Russia, India, South Korea, Pakistan, Bangladesh, Egypt, Tanzania, Brazil, and others |
|
Industry Experience |
Parent-group R&D team with over 30 years of experience in the NVP and PVP industry chain |
|
Production Footprint |
Three integrated manufacturing facilities supporting the NVP-to-PVP value chain |
Customer-Recognized Quality
From the original company description - meaning preserved, language professionalized for international buyers:
Our goal has always been to deliver the quality and consistency that pharmaceutical customers require. Since Kema's founding in June 2017, our products have earned consistent praise from customers across China - a recognition we are now bringing to international markets. The strength behind this recognition is the depth of experience in our supply chain: our parent group has over 30 years of experience in the NVP and PVP industry, and our three integrated manufacturing facilities work together to build the complete NVP-to-PVP value chain. This combination of proven quality, deep technical experience, and fully integrated production is what allows us to support pharmaceutical customers who require multi-pharmacopeial compliance, batch-to-batch consistency, and reliable long-term supply.
We are committed to becoming a backbone enterprise in China's PVP industry, and we believe that commitment is most clearly demonstrated through the quality of every batch we ship to your facility.

About Ulanqab Kema New Material Co., Ltd.
Ulanqab Kema New Material Co., Ltd. is a high-tech enterprise specializing in the research, development, and manufacture of N-vinyl-2-pyrrolidone (NVP), polyvinylpyrrolidone (PVP K-series), copovidone (VA64), crospovidone (PVPP), and povidone-iodine (PVP-I). Founded in June 2017 in Mengwei New Material Industrial Park, Qahar Right Rear Banner, Ulanqab City, Inner Mongolia, the company is registered with RMB 59.58 million capital and RMB 110 million fixed assets, employs 150 people, and records annual sales exceeding RMB 200 million. The parent group has over 30 years of experience in the NVP and PVP industry chain, and Kema's three integrated manufacturing facilities work together to deliver the full NVP-to-PVP value chain to pharmaceutical, food, cosmetic, and industrial customers worldwide.
Kema's products serve more than 400 customers worldwide across pharmaceuticals, food & beverage, cosmetics, new energy batteries, water treatment, and industrial applications. The company holds ISO 9001, ISO 14001, ISO 45001, ISO 50001, GMP, and IATF 16949 certifications, with EU/UK/Turkey/Korea REACH registrations, HALAL, FDA DMF filings, and 39 patents. Export markets include the USA, UK, Portugal, Italy, Russia, India, South Korea, Pakistan, Bangladesh, Egypt, Tanzania, Brazil, and others.
Packaging & Storage
Standard export packaging: 25 kg moisture-proof fiber drums with double polyethylene liners, palletized and stretch-wrapped. Custom-specific labeling
Storage: Keep in tightly closed containers in a cool, dry place (15 – 25°C recommended, not exceeding 30°C), protected from moisture. Under proper storage conditions, shelf life is 24 months from the date of manufacture.
Frequently Asked Questions
Is your company the manufacturer of polyvinylpyrrolidone 30 for pharmaceutical, or a trading company?
We are the manufacturer. Ulanqab Kema New Material Co., Ltd. owns and operates the production facility in Mengwei New Material Industrial Park, Qahar Right Rear Banner, Ulanqab City, Inner Mongolia, China. We produce NVP monomer and the full PVP polymer family in-house. Our Hangzhou trading office (Clair / Shelly) handles international sales, samples, and logistics coordination.
Can we receive free samples of PVP K30 before placing a commercial order, and what is the MOQ?
Yes. We provide free evaluation samples of 100 g–500 g for qualified pharmaceutical buyers. Samples are dispatched within 2–3 business days and arrive by international express in 5–10 business days. Each sample includes a batch-specific COA so you can verify K-value, viscosity, residual monomer, and impurity profile before scaling up. Standard MOQ is 1000 kg, but we can make adjustments for initial commercial orders, with tiered pricing for full-container loads.
Why is polyvinylpyrrolidone 30 for pharmaceutical considered safe for human drug products, including parenteral and ophthalmic use?
PVP K30 has been used in pharmaceutical formulations since the 1940s with a well-characterized safety profile. It is non-ionic, physiologically inert, and chemically stable across pH 1–14. Its molecular weight range (44,000–58,000 Da) is well below the renal clearance threshold of approximately 70,000 Da, so any absorbed fraction is rapidly excreted unchanged. PVP K30 is listed in the FDA Inactive Ingredients Database for oral, topical, ophthalmic, and parenteral routes, and is monographed in USP-NF, EP, JP, and CP.
How is PVP K30 used to improve the bioavailability of poorly soluble APIs (BCS Class II)?
PVP K30 is the most widely used polymer carrier for amorphous solid dispersions of BCS Class II active pharmaceutical ingredients. Because of PVP's hydrogen-bond interaction with many drug molecules and its ability to inhibit crystallization during storage, the API can be maintained in a high-energy amorphous form at typical drug-to-polymer ratios of 1:2 to 1:10. This significantly improves apparent aqueous solubility, dissolution rate, and oral bioavailability compared with the crystalline drug alone. Common manufacturing methods include spray drying, hot-melt extrusion, and co-precipitation.
What regulatory documentation and DMF support do you provide for global product registration?
Pharmaceutical-grade PVP K-series are FDA Drug Master File (DMF) filed, and we provide DMF reference letters and supporting documentation for FDA, EMA, and other authority submissions. CEP-related documentation, EU/UK/Turkey/Korea REACH registration confirmations, HALAL certificates, GMP declaration, and free-sale certificates are available on request. Tell us your target market and registration timeline, and our regulatory team will prepare the documentation package specific to that destination.
How do you ensure batch-to-batch consistency of K-value, viscosity, and impurity profile for pharmaceutical-grade PVP K30?
Consistency starts at the monomer: we produce NVP in-house on a continuous line with closed-loop process control, then polymerize under validated parameters. Every batch undergoes full pharmacopeial testing - K-value (USP Fikentscher method, 1% aqueous solution, 25°C), viscosity (10% aqueous solution, Brookfield), residual NVP monomer (HPLC), aldehydes, peroxides, hydrazine, heavy metals (USP <231> / ICH Q3D), 2-pyrrolidone, formic acid, and microbiological limits (USP <61>/<62>) - before release. Our pharmaceutical-grade PVP batch pass rate is 99.98%, with K-value reproducibility within ±1 unit batch to batch. Retention samples are kept for 24 months for full traceability.
Can we audit your manufacturing facility, and do you support remote audits for international pharmaceutical customers?
Yes, we welcome customer audits at our Inner Mongolia facility. Our GMP clean production workshops are open to qualified buyers by appointment. For overseas customers who cannot travel, we also support remote / virtual audits with live video walkthroughs, documentation review, and Q&A sessions with our quality and regulatory teams. Our Hangzhou trading office can arrange logistics and interpretation support for any audit visit. To schedule an audit or request a quotation, email clair@wlcbcoma.com or contact US.
Hot Tags: polyvinylpyrrolidone 30 for pharmaceutical, China, suppliers, manufacturers, factory, wholesale, buy, free sample, Povidone Pvp K30, Povidone K30, Pvp K30, Povidone K 90 Usp, Povidone K25, Synthetic Polymer Vehicle Povidone
Send Inquiry